About us

At a Glance

Axon Neuroscience is a clinical-stage biotech company developing disease-modifying immunotherapeutics for Alzheimer's disease and Frontotemporal lobar degeneration. Ground-breaking discoveries in Alzheimer’s disease research made by AXON Neuroscience enabled the company to create a therapeutic platform of global importance. The target products of strategic importance in this platform are revolutionary therapeutic candidate vaccines for treatment of Alzheimer's disease and Frontotemporal lobar degeneration.

AXON Neuroscience has developed unique animal models that reproduce Alzheimer’s disease and allow for a swift and effective pre-clinical validation of efficacy of new therapeutics and pre-clinical evaluation of diagnostic tools.

Strategically targeted research and development enable AXON Neuroscience to prepare for future production of an extensive assortment of disease modifying pharmaceuticals and diagnostic methods for Alzheimer’s disease.

"Alzheimer’s disease has long been the modern plague of mankind. Despite momentous efforts across the industry, an effective prevention and treatment has not yet been discovered. Axon is on a mission to change this. With over two decades of dedicated research, our expert team is leading industry on the path to finding a tau based treatment. The very positive results from our landmark Phase II trial underpin our confidence, and strengthen our motivation to get a treatment to patients as soon as possible."

— Michal Fresser, CEO Axon Neuroscience

Mission

Infographic Infographic
  • 7,6 billion worldpopulation
  • 636 million world population over 65
  • 47 million dementia cases
The mission of AXON Neuroscience is to discover and deliver disease modifying immunotherapeutics and enhance the quality of life for patients suffering from Alzheimer's disease and Frontotemporal lobar degeneration.

Axon's Story

August 2017

AXON Neuroscience initiated its Phase 1 study in patients with non-fluent variant of primary progressive aphasia and enrolled the first patient.

April 2017

AXON Neuroscience has completed patients’ recruitment in the phase II study ADAMANT in patients with Alzheimer’s disease.

December 2016

AXON Neuroscience published the results of the Phase 1 study of its active vaccine AADvac1 in patients with Alzheimer’s disease.

June 2016

AXON Neuroscience has started the Phase II study as the first patient has been vaccinated with the active tau vaccine AADvac1.

April 2016

AXON Neuroscience becomes a founding member of the Society for CSF Analysis and Clinical Neurochemistry.

March 2016

AXON Neuroscience presented at the 14th Springfield Symposium on Advances in Alzheimer Therapy two topics from its disease modifying AD program. See Press Release for more information.

November 2015

AXON Neuroscience attended the Clinical Trials on Alzheimer´s Disease conference (CTAD) in Barcelona, on November 5-7, 2015.

July 2015

AXON Neuroscience as a gold level sponsor has organized a Symposium at the Alzheimer´s Association International Conference (AAIC), the largest Alzheimer´s and dementia conference in the world, in Washington, D.C.

March 2015

AXON Neuroscience successfully finished phase 1 Study with AADvac1

December 2014

Recruitment of patients for AADvac1 phase I study has been completed

August 2014

AXON Neuroscience and MRC Technology announced successful humanization of Anti-Tau Monoclonal Antibody for Alzheimer’s disease therapy. See Press Release for more information

July 2014

Prof. Michal Novak presented new clinical data from the ongoing AADvac1 phase I study at the Alzheimer Association International Conference in Copenhagen (July 12-17, 2014)

December 2013

Axon Neuroscience has received final approval from the Regulatory Authority and Central Ethics Committee in Graz to start a AADvac1 phase I follow-up study

July 2013

The first patient was vaccinated with AADvac1

May 2013

First-in-man clinical trial with the first active immunotherapy directed against neurofibrillary tau pathology in Alzheimer’s disease was approved by the Regulatory Authority and Central Ethics Committee in Graz

March 2013

AXON Neuroscience presented its therapeutic strategies at the AD/PD 2013 international conference in Florence

2012

AXON Neuroscience started GMP (good manufacturing practice) vaccine production and finished its GLP (good laboratory practice) toxicology and safety pharmacology studies

2009-2011

AXON Neuroscience confirmed the in vivo efficacy of its vaccines in preclinical studies using AD transgenic rat models

2009

AXON Neuroscience uncovered the mechanism of how Alzheimer tau induces neuroinflammation

AXON Neuroscience discovered the most vulnerable area of Alzheimer tau - the Achilles heel of Alzheimer tau

Using knowledge of the 3D structure of the tau Achilles heel, AXON Neuroscience produced tau peptide vaccines

2007

AXON Neuroscience initiated a revolutionary immunotherapy program

2006

AXON Neuroscience showed that Alzheimer tau is an inducer of oxidative stress

2003

AXON Neuroscience developed the first AD transgenic rat model and validated Alzheimer tau as a major cause of AD neurodegeneration. The model was presented in the "Hot Topics Session" at the 9th International Conference on AD (ICAD), Philadelphia in July 2004

2002

AXON Neuroscience has developed an integrated set of new immunological, biochemical, and cell assays devoted to drug screening and validation

2001

AXON Neuroscience discovered and characterized a particular form of the truncated tau protein with a causal role in AD - Alzheimer tau

1999

AXON Neuroscience was founded as a biotech company focusing on Alzheimer's disease therapy (Michal Novak was a co-founder of the company)

1994

Michal Novak proposed that truncated tau species display features similar to prions and therefore he designated them as tauons

1991

Michal Novak discovered tau truncation as the most productive post-translational modification in Alzheimer's disease and simultaneously designated truncated tau as a driving force of the neurofibrillary degeneration in Alzheimer's disease

1988

While working with three Nobel Laureates - Cesar Milstein, Aaron Klug and John Walker - at MRC LMB Cambridge, UK, Michal Novak created a monoclonal antibody (MN423) that was instrumental in the discovery of tau protein as an integral constituent of neurofibrillary tangles – a major hallmark of Alzheimer's disease

Leadership

Michal Fresser, Chief Executive Officer

Michal Fresser first joined Axon in 2013 as a board member & general counsel to the firm. Since then, he has been appointed as Chief Executive Officer of Axon in 2019, while he also serves as Chairman of the Board of Directors of Axon’s two subsidiaries – Axon Neuroscience CRM Services SE and Axon Neuroscience R&D Services SE.

Prior to his arrival at Axon, Michal had established a career in both legal advisory and consulting. There, he covered multiple sectors, gaining extensive knowledge on mergers and acquisitions, cross-border transactions, and both corporate and competition law.

Norbert Žilka, Chief Science Officer

Norbert has been with Axon since its establishment in 1999. He has played a key role in guiding discoveries and has helped transform Axon’s portfolio of products, which eventually led to his appointment as CSO in 2015.

He has co-authored the project Synaptic Dysfunction in Alzheimer’s Disease (Marie Curie Innovative Training Network). In addition, he serves as the national coordinator and Chairman of the Neuroscience session at the first Frontiers of Science Meeting.

Norbert holds a PhD in Immunology from the Slovak Academy of Sciences (SAS) and is an associate professor at the Institute of Neuroimmunology at SAS.

Ladislav Satko, Chief Financial Officer

Ladislav Satko has over fifteen years’ experience leading finance and operations for international businesses. In 2003, Ladislav worked in a financial role for a European construction business. Following this, he was Head of Finance for one of the largest central European publicly traded real estate companies.

In November 2011 he was appointed as Chief Financial Officer of Axon, where he is responsible for financial, human resources and IT matters at the company.

Ladislav holds a Master’s degree in Business Administration from the Economic University in Bratislava.

Roman Sivak, Managing Director of AXON Neuroscience CRM and R&D

Roman serves as Managing Director of Axon’s two subsidiaries – Axon Neuroscience CRM Services SE and AXON Neuroscience R&D Services SE, having previously been in a role as CEO of Axon from 2011 until 2019.

He has extensive experience in the financial sector and has served in various management positions for start-up projects and acquisitions. He has also served as a member of supervisory boards of multiple start-up projects and acquisitions in industrial and financial sectors.

Roman graduated with a Master of Economics degree from the University of Economics in Bratislava.

Prof. Michal Novák, Co-Founder of AXON Neuroscience

Prof. Novak is a serving board member for Axon, having co-founded the company in 1999.

He is a world-renowned scientist, and prior to founding Axon, spent 10 years at the Laboratory of Molecular Biology in Cambridge in a team with three Nobel Laureates. There, Prof. Novak created a monoclonal antibody (MN423), which has driven revolutionary discoveries towards the understanding the role of tau protein in Alzheimer’s disease.

Prof. Novak is also the founder of The Institute of Neuroimmunology of the Slovak Academy of Sciences, The Memory Foundation, The Slovak Alzheimer’s Association and the Slovak Society for Neuroscience, while also serving as the co-founder of the EU Joint Programme- Neurodegenerative Disease Research (JPND). In 2016, he was awarded with the World Health Organisation’s prize for Research in Health Care for the Elderly and in Health Promotion.

Advisory Board

AXON Neuroscience has assembled an international team of leading experts in the field of Alzheimer’s disease and clinical drug development to support the designs, conducts, and analyses of AXON Neuroscience clinical trials for new treatments of Alzheimer’s disease and other related neurodegenerative disorders.

Bengt Winblad

MD, Prof., Division of Neurogeriatrics, Karolinska Inst., Stockholm, SE

Philip Scheltens

Dr, Prof., Director of Alzheimer center, VUmc, Amsterdam, NL

Howard Feldman

MD, FRCP(C), Director of UC San Diego ADCS, San Diego, USA

John Harrison

Assoc Prof., Alzheimer center, VUmc, Amsterdam, NL/UK

Khalid Iqbal

Professor and Chairman, Department of Neurochemistry, at the New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York, USA

Richard Kay

Expert in Statistics, an Honorary Visiting Professor at the School of Pharmacy, University of Cardiff and a member of the Faculty of Pharmaceutical Medicine. Editor of the journal Pharmaceutical Statistics.

Reinhold Schmidt

Univ.-Prof. Dr.med.univ , Universitätsklinik für Neurologie, Graz, AT

Lutz Frölich

MD, Prof., Head of Clinics of Gerontopsychiatry, Mannheim, GE

Jakub Hort

MD, Prof., Head of Counseling Center for Cognitive Disfunctions, FN Motol, Prague, CZ

Kaj Blennow

Head of Research on Neurochemical Pathogenesis and Diagnostics at the University of Gothenburg